2176423 Ontario Ltd. Purchases 213,800 Shares of Andean Precious Metals Corp. (CVE:APM) Stock

Andean Precious Metals Corp. (CVE:APM) insider 2176423 Ontario Ltd. acquired 213,800 shares of Andean Precious Metals stock in a transaction that occurred on Wednesday, October 2nd. The stock was acquired at an average price of C$1.38 per share, with a total value of C$294,530.88.

2176423 Ontario Ltd. also recently made the following trade(s):

• On Tuesday, September 24th, 2176423 Ontario Ltd. purchased 700,000 shares of Andean Precious Metals stock. The stock was bought at an average cost of C$1.36 per share, with a total value of C$952,000.00.
• On Monday, September 16th, 2176423 Ontario Ltd. acquired 204,600 shares of Andean Precious Metals stock. The shares were bought at an average cost of C$1.14 per share, for a total transaction of C$233,141.70.

Andean Precious Metals Stock Down 7.0 %

Andean Precious Metals stock opened at C$1.46 on Friday. The business’s 50 day moving average price is C$1.12. Andean Precious Metals Corp. has a 1-year low of C$0.54 and a 1-year high of C$1.60. The company has a market cap of C$218.07 million, a price-to-earnings ratio of 3.95 and a beta of 1.13.

Andean Precious Metals (CVE:APM) last released its quarterly earnings results on Tuesday, August 13th. The company reported C$0.08 earnings per share for the quarter, hitting the consensus estimate of C$0.08. The firm had revenue of C$95.47 million for the quarter. Andean Precious Metals had a net margin of 23.75% and a return on equity of 41.08%. As a group, research analysts anticipate that Andean Precious Metals Corp. will post 0.3792135 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Desjardins lifted their target price on Andean Precious Metals from C$1.60 to C$1.70 and gave the company a “buy” rating in a report on Tuesday, September 3rd.

About Andean Precious Metals

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases.